Business Wire

1. Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company 3/30/2026

   Asha Therapeutics has announced its rebranding as First Atom Therapeutics (“First Atom”), marking the company’s evolution as a zero-shot de novo drug design company using AI-enabled molecular design technology to create transformative medicines for neurodegenerative, neuro-oncological, and rare diseases.

2. SEQSTER Unveils AI-Powered Patient Screening For Clinical Trials 3/26/2026

   SEQSTER PDM, Inc. (“SEQSTER”), the leading healthcare technology company powering the connection, collection, and orchestration layer of patient health data, today launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in minutes.

3. Simulations Plus Announces Strategic Collaboration Programs For AI-Enabled Modeling 3/26/2026

   Simulations Plus, Inc. (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle.

4. Sinopia Biosciences Awarded NCI Grant To Advance LEADS Drug Discovery Platform For Oncology 3/24/2026

   Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS (LEarn And DiScover) drug discovery platform, today announced it has been awarded a research grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the application of its metabolomics-driven discovery capabilities to oncology.

5. Ionis Announces Zilganersen New Drug Application For Alexander Disease (AxD) Accepted By FDA For Priority Review 3/23/2026

   Ionis Pharmaceuticals, Inc. oday announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), a rare, progressive and often fatal neurological condition.

6. IntraBio Announces Submission Of Supplemental New Drug Application For Levacetylleucine For Ataxia-Telangiectasia 3/20/2026

   IntraBio Inc. today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T), a rare, progressive, inherited neurodegenerative disorder.

7. Alloy Therapeutics Enters Into Agreement To Advance Novel Antibody Discovery Platform 3/17/2026

   Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies.

8. PsiQuantum And National Cancer Center Japan Announce New Strategic Partnership To Accelerate Drug Discovery For Healthcare 3/12/2026

   PsiQuantum announced today that the company has signed a collaborative research agreement with the National Cancer Center Japan, a leading cancer treatment and research facility, to advance applications in oncology and healthcare for utility-scale quantum computers.

9. Precision BioSciences Receives FDA Fast Track Designation For PBGENE-DMD And Announces Duchenne Muscular Dystrophy Investor Event 3/9/2026

   Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

10. Ono Pharma Announces New Drug Discovery Collaboration With Congruence Therapeutics In The Priority Areas Of Neurology And Immunology 3/2/2026

    Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that it has entered into an agreement to expand the drug discovery collaboration agreement with Congruence Therapeutics (Headquarters: Montreal, Quebec, Canada; CEO: Clarissa Desjardins; “Congruence”) for the discovery of novel small molecule modulators against multiple protein targets in the areas of neurology and immunology.